DRSG minutes 1/10/23

1. Introductions/attendees:

                Michael Dzierlenga – Chair <Dzierlenga.Michael@epa.gov>

                Chase (Chastain) Anderson – Chair Elect

                Andrew Williams – Past Chair

                Paul Schlosser – Vice Chair

                Shuyi Feng – Student/Postdoc Liaison

 Allen Davis

                Dustin Kapraun

                Scott Auerbach

1. Secretary/Treasurer position is still open.  Relatively light duties. If you know someone who would be willing, please help put us in touch.
2. Because the current officers were appointed by the (outgoing) executive committee, all officer positions should be subject to a vote this coming fall (2023):
	1. VC (2 yr), Secretary/Treasurer (1 yr), trustee-at-large (2 yr) and trustee-at large (1 yr).
	2. After that we should return to 2-year terms for the vice-chair and secretary/treasurer, staggered with each other, and likewise for the two at-large positions. (President-elect/president/past-president is a 3-year term.)
	3. We may have pro-forma elections for subsequent years (i.e., with one candidate each proposed for open positions). Balloting would allow for other nominees but based on recent history it is unlikely that positions will be contested.
3. Abstract submissions for SRA annual meeting come up in June. The SRA program committee now puts together sessions from independent abstracts, but DRSG may still be able to help organize/submit scientific sessions. Michael will check with the secretariat to clarify. Discussions of these can occur in April/May.
4. Discussion of March webinar options
	1. Transciptomics [addressing dose-additivity?]
	2. Animal Free Safety Assessment (AFSA)/NAMs
	3. Chase will evaluate these two options for March
5. Subsequent webinar ideas
	1. PBPK-BMD integration: \*maybe\* later this year
	2. NAMs / Regulatory Acceptance
	3. Perspective from pharma on dose-response analysis
		1. Annie Lumen, FDA è pharma
		2. Cindy Lucanti (sp?) (Kapraun contact)
		3. Michael could also contact Salil Pendse. Miyoung Yoon (FDA) is also a possible speaker.
	4. Could do two shorter talks (30 min each) from students or postdocs
	5. Professional development talk, Tony Williams, EPA
	6. Intro to dose-response analysis
		1. Webinar or course at annual meeting
		2. Newer generation seems to not understand reasons for traditional tox studies
		3. Issue of complexity (e.g., sensitivity to initial conditions), interactions among systems in whole organisms (?)
		4. What do model systems represent?
		5. Why do we use them?
		6. Ethical issues
6. Webinar outreach
	1. Michael can use DRSG list-serve
	2. Can post to DRSG website
	3. LinkedIn
	4. Want to be able to post to academic departments
	5. SRA “Ways to Engage” email
7. Planning to include business meeting on webinar months, maybe 30 min before or after webinar.
8. Name and purpose of group
	1. Current bylaws can be interpreted narrowly
	2. Suggest re-wording bylaws to encourage broader interpretation
	3. Re-branding: changing our name to be more inclusive
	4. Goal: single vote for officers and bylaws later this fall
		1. To get there, have proposed changes ready to share in August
		2. Name change could be included or taken to final vote at annual meeting…
		3. Dustin: “I wouldn't worry about missing out on hearing opinions of those people who only participate in DRSG once each year at the SRA Annual Meeting. I think those people who are most interested and involved in DRSG will either attend DRSG monthly meetings or respond to email.”